Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
Previous Symbol
CUSIPN/A
Phone972-865-2219
Debt
Debt-to-Equity Ratio2.10
Current Ratio6.04
Quick Ratio6.04
Price-To-Earnings
Trailing P/E Ratio-29.80
Forward P/E Ratio-19.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.06 million
Price / Sales36.68
Cash FlowN/A
Price / Cash FlowN/A
Book Value($5.62) per share
Price / Book-10.55
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-130.01%
Return on EquityN/A
Return on Assets-34.08%
Miscellaneous
Employees93
Outstanding Shares29,720,000
Market Cap$1.72 billion
OptionableOptionable
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals Inc (NASDAQ:RETA) released its quarterly earnings data on Wednesday, November, 7th. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.28. The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $9.50 million. View Reata Pharmaceuticals' Earnings History.
When is Reata Pharmaceuticals' next earnings date?
What price target have analysts set for RETA?
6 Wall Street analysts have issued twelve-month target prices for Reata Pharmaceuticals' stock. Their predictions range from $92.00 to $139.00. On average, they anticipate Reata Pharmaceuticals' stock price to reach $111.80 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.
What is the consensus analysts' recommendation for Reata Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (11/28/2018)
- 2. Cantor Fitzgerald analysts commented, "We rate RETA Overweight. We believe lead candidates bard and omav have a novel MOA and applicability in several diseases characterized by mitochondrial dysfunction, oxidative stress and chronic inflammation/fibrosis. The company is addressing kidney disease caused by several rare conditions, many with no approved therapies. Recent data point to a differentiated, favorable efficacy & safety profile, not only for AS-CKD, but we believe also read on the PoS in other CKD indications, & bode well for larger more advanced trials." (10/1/2018)
Has Reata Pharmaceuticals been receiving favorable news coverage?
News headlines about RETA stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a news impact score of 2.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next few days.
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH) and Emergent Biosolutions (EBS).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- Mr. J. Warren Huff, Chairman, CEO & Pres (Age 64)
- Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 39)
- Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 48)
- Mr. Jason D. Wilson, CFO & VP of Strategy (Age 48)
- Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Who are Reata Pharmaceuticals' major shareholders?
Reata Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.50%), Vanguard Group Inc. (4.00%), Franklin Resources Inc. (2.89%), Point72 Asset Management L.P. (2.53%), Emerald Advisers Inc. PA (1.59%) and Emerald Mutual Fund Advisers Trust (1.50%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Which major investors are selling Reata Pharmaceuticals stock?
RETA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Emerald Advisers Inc. PA, Sphera Funds Management LTD., Emerald Mutual Fund Advisers Trust, LBJ Family Wealth Advisors Ltd., JPMorgan Chase & Co., JPMorgan Chase & Co. and P.A.W. Capital Corp. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.
Which major investors are buying Reata Pharmaceuticals stock?
RETA stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Vanguard Group Inc., BlackRock Inc., EAM Investors LLC, Candriam Luxembourg S.C.A., Columbus Circle Investors and American Century Companies Inc.. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $59.31.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $1.72 billion and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.
What is Reata Pharmaceuticals' official website?
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
